FDA-approved product exists

Semaglutide

Also called Wegovy, Ozempic, Rybelsus.

Semaglutide has FDA-approved products for specific uses. This page cites 3 sources, and the strongest evidence comes from human trials.

Status: FDA-approved product exists
Form: Pen injection
Half-life: about 7 days, FDA label
Strongest evidence: Human trials
Cited claims: 2
Last updated: November 6, 2026

What the evidence says

Each claim names the kind of study behind it, what it can't tell you, and where it comes from.

Human trials
Semaglutide supports weight loss in adults with obesity and improves blood glucose control in adults with type 2 diabetes.
Limits: These benefits were studied in separate controlled trials of specific prescription products. Formulations have different indications, and individual results vary.
- Wilding et al., 2021: Once-Weekly Semaglutide in Adults with Overweight or Obesity
- Sorli et al., 2017: Semaglutide in type 2 diabetes, SUSTAIN 1
Human trials
Injected semaglutide has an elimination half-life of about one week.
Limits: The modeled absorption rate of 0.05/hour is an assumption for an injection curve. It is not a label parameter or a model for oral semaglutide.
- FDA label: Wegovy injection, clinical pharmacology

Regulatory status

United States

FDA-approved products exist for specific indications; formulations have different labels.

FDA label: Wegovy injection, clinical pharmacology

Half-life

The FDA label lists a half-life of about 7 days. Here is what that looks like for a weekly schedule, as Peptiday draws it. It's a population estimate, not a measurement of your blood level.

Illustration relative to the modeled peak. The half-life comes from the label and absorption is assumed. It isn't a blood measurement, so don't use it to choose amounts or timing.